Polaris Pharmaceuticals-KY Announces Remuneration Committee Member Appointments

Polaris Pharmaceuticals-KY (6550) announced on May 15, 2026, that its board of directors has resolved to appoint new members to the Remuneration Committee. This change follows the comprehensive re-election of directors, including independent directors, at the company's 2026 annual general meeting. The previous committee members' terms have expired. The newly appointed members are Zhao Yingcheng, Di Shijie (Associate Professor at the University of Hong Kong), and Zhang Zhigang (CEO of Zhongen Biomedical). The effective date for the new appointments is May 15, 2026.
Corporate GovernanceNQ 50/100出典:PR Times

📋 Article Processing Timeline

  • 📰 Published: May 16, 2026 at 12:57
  • 🔍 Collected: May 16, 2026 at 12:57 (0 min after Published)
  • 🤖 AI Analyzed: May 16, 2026 at 14:45 (1h 48m after Collected)
Announcement Date: May 16, 2026
Spokesperson Date: May 15, 2026
Spokesperson Time: 21:16:40
Company Code: 6550
Company Name: Polaris Pharmaceuticals-KY
Subject: Announcement of the Board of Directors' resolution to appoint members of the Remuneration Committee
Clause Compliance: Clause 6
Date of Fact Occurrence: May 15, 2026
Description:
1. Date of Change: 115/05/15 (May 15, 2026)
2. Functional Committee Name: Remuneration Committee
3. Former Members:
Independent Director: Wei Zongde
Independent Director: Zhao Yingcheng
Independent Director: Wen (Ri Min) Guolan
4. Former Members' Brief:
Independent Director: Wei Zongde
Independent Director: Zhao Yingcheng
Independent Director: Wen (Ri Min) Guolan
5. New Members:
Independent Director: Zhao Yingcheng
Independent Director: Di Shijie
Independent Director: Zhang Zhigang
6. New Members' Brief:
Independent Director: Zhao Yingcheng / Independent Director of this company
Independent Director: Di Shijie / Associate Professor at the University of Hong Kong
Independent Director: Zhang Zhigang / CEO of Zhongen Biomedical
7. Change Details (Please enter 'Resignation', 'Dismissal', 'Term Expiration', 'Death', or 'New Appointment'):
Term Expiration
8. Reason for Change: Comprehensive re-election of directors (including independent directors) at the 2026 Annual General Meeting.
9. Original Term (e.g., xx/xx/xx ~ xx/xx/xx): 112/09/26 ~ 115/06/11 (September 26, 2023 ~ June 11, 2026)
10. New Effective Date: 115/05/15 (May 15, 2026)
11. Other Matters to be Notified: None

FAQ

What is the company code for Polaris Pharmaceuticals-KY?

The company code is 6550.

What was the main announcement regarding the Remuneration Committee?

The company announced the appointment of new members to its Remuneration Committee.

When did the changes to the Remuneration Committee take effect?

The changes took effect on May 15, 2026.

Why were there changes in the Remuneration Committee?

The changes were due to the completion of the previous term and the comprehensive re-election of directors, including independent directors, at the 2026 annual general meeting.